Evaluation of aldosterone antagonist utilization in heart failure with reduced and preserved ejection fraction at an academic medical center

Keywords: Heart Failure, Mineralocorticoid Receptor Antagonists, Drug Utilization, Guideline Adherence, Clinical Audit, United States

Abstract

Background: Aldosterone antagonists (AA) have historically been underutilized despite evidence that they reduce morbidity, mortality, and readmission rates to the hospital when used appropriately.

Objective: We sought to determine if AAs were being prescribed in accordance with the 2013 ACCF/AHA guidelines and if there was any benefit surrounding 30-day readmissions or 30-day mortality for patients taking AAs with heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF).

Methods: We performed a retrospective chart review of adult patients who were discharged between October 1, 2015 and February 1, 2016 with any ICD-10 code for heart failure to assess compliance with guideline directed medical therapy. At baseline, patients were stratified by HFpEF and HFrEF. Patients were excluded if they died during the admission, discharged with hospice care, received a heart transplant or ventricular assist device, if they were miscoded or left against medical advice. Descriptive statistics, and Chi Square were used to evaluate the data.

Results: We reviewed 601 patient charts for eligibility in our study, and determined 438 met the criteria for inclusion. Ninety-seven patients (22%) received an AA. Within the HFrEF group, only 37% of patients who were eligible per 2013 ACCF/AHA guidelines, received an AA at time of discharge. Fourteen percent of HFpEF patients were discharged on an AA. We found a trend towards decreased rates of our 30-day outcomes in patients who took AAs in both the HFpEF and HFrEF groups.

Conclusions: AAs were underutilized during the timeframe we evaluated, despite the evidence for their use.

Downloads

Download data is not yet available.

References

Butler J, Ezekowitz JA, Collins SP, Givertz NM, Teerlink JR, Walsh MN, Albert NM, Westlake Canary CA, Carson PE, Colvin-Adams M, Fang JC, Hernandez AF, Hershberger RE, Katz SD, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, Stough WG, Starling RC. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction: Heart Failure Society of America Guidelines Committee. J Card Fail. 2012;18(4):265-281. https://dx.doi.org/10.1016/j.cardfail.2012.02.005

Mizuno Y, Yoshimura M, Yasue H, Sakamoto T, Ogawa H, Harada, Nakayama M, Nakamura S, Ito T, Shimasaki Y, Saito Y, Nakao K. Aldosterone production is activated in failing ventricle in humans. Circulation. 2001;103(1):72-77.

Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13(8 Suppl B):9-20.

Vizzardi E, Regazzonii V, Caretta G, Gavazzoni M, Sciatti E, Bonadei I, Trichaki E, Raddino R, Metra M. Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives. Int J Cardiol Heart Vessel. 2014;3:6-14. https://dx.doi.org/10.1016/j.ijchv.2014.03.005

Ghazi L and Drawz P. Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy. F1000Res. 2017;6. https://dx.doi.org/10.12688/f1000research.9692.1

Maron BA, Leopold JA. Aldosterone receptor antagonists: effective but often forgotten. Circulation. 2010;121(7):934-939. https://dx.doi.org/10.1161/CIRCULATIONAHA.109.895235

Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341(10):709-717. https://dx.doi.org/10.1056/NEJM199909023411001

Pitt B, Zannad F, Remme WJ, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309-1321. https://dx.doi.org/10.1056/NEJMoa030207

Zannad F, Mcmurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21. https://dx.doi.org/10.1056/NEJMoa1009492

Udelson JE. Heart failure with preserved ejection fraction. Circulation. 2011;124(21):e540-3. https://dx.doi.org/10.1161/CIRCULATIONAHA.111.071696

Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-1392. https://dx.doi.org/10.1056/NEJMoa1313731

Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O'Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation. 2015;131(1):34-42. https://dx.doi.org/10.1161/CIRCULATIONAHA.114.013255

Redfield MM. Heart failure with preserved ejection fraction. N Engl J Med. 2016;375(19):1868-1877. https://dx.doi.org/10.1056/NEJMcp1511175

Parikh KS, Sharma K, Fiuzat M, Surks HK, George JT, Honarpour N, Depre C, Desvigne-Nickens P, Nkulikiyinka R, Lewis GD, Gomberg-Maitland M, O'Connor CM, Stockbridge N, Califf RM, Konstam MA, Januzzi JL Jr, Solomon SD, Borlaug BA, Shah SJ, Redfield MM, Felker GM. Heart failure with preserved ejection fraction expert panel report. JACC Heart Fail. 2018;6(8):619-632. https://dx.doi.org/10.1016/j.jchf.2018.06.008

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240-e327. https://dx.doi.org/10.1161/CIR.0b013e31829e8776

Yancey CW, Januzzi Jr JL, Allen LA, Butler J, Davis LL, Fonarow GC, Ibrahim NE, Jessup M, Lindenfeld J, Maddox TM, Masoudi FA, Motiwala SR, Patterson JH, Walsh MN, Wasserman A. 2017 ACC Expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection Fraction. J Am Coll Cardiol. 2018;71(2):201-230. https://dx.doi.org/10.1016/j.jacc.2017.11.025

Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14(10):591-602. https://dx.doi.org/10.1038/nrcardio.2017.65

Ng TM, Tsai F, Khatri N, Barakat MN, Elkayam U. Venous thromboembolism in hospitalized patients with heart failure. Circ Heart Fail. 2010;3(1):165-173. https://dx.doi.org/10.1161/CIRCHEARTFAILURE.109.892349

Sharma K, Kass DA. Heart failure with preserved ejection fraction. Mechanisms, clinical features, and therapies. Circ Res. 2014;115(1):79-96. https://dx.doi.org/10.1161/CIRCRESAHA.115.302922

Punnoose LR, Givertz MM, Lewis EF Pratibhu P, Stevenson LW, Desai AS. Heart failure with recovered ejection fraction: a distinct clinical entity. J Card Fail. 2011;17(7):527-532. https://dx.doi.org/10.1016/j.cardfail.2011.03.005

Greene SJ, Butler J, Albert NM, Devore AD, Sharma PP, Duffy CI, Hill CL, McCague K, Mi X, Patterson JH, Spertus JA, Thomas L, Williams FB, Hernandez AF, Fonarow GC. Medical therapy for heart failure with reduced ejection fraction. The CHAMP-HF registry. J Am Coll Cardiol. 2018;72(4):351-366. https://dx.doi.org/10.1016/j.jacc.2018.04.070

Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, van Veldhuisen DJ, Zannad F, Krum H, Mukherjee R, Vincent J, EPHESUS Investigators. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46(3):425-431. https://dx.doi.org/10.1016/j.jacc.2005.04.038

Published
2019-03-10
How to Cite
1.
Bradley D, Nappi J. Evaluation of aldosterone antagonist utilization in heart failure with reduced and preserved ejection fraction at an academic medical center. Pharm Pract (Granada) [Internet]. 2019Mar.10 [cited 2019Sep.18];17(1):1376. Available from: https://pharmacypractice.org/journal/index.php/pp/article/view/1376
Section
Original Research